Development and testing of a novel precision tumour measurement device intended for pre-clinical research sector to reduce the consumption of animal models

开发和测试一种新型精密肿瘤测量装置，用于临床前研究领域，以减少动物模型的消耗

• 批准号: 10053141
• 金额: $ 27.77万
• 依托单位: VERINNOGEN LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10053141
• 关键词: Development; testing; novel; precision; tumour

Currently, pre-clinical trials for anticancer drugs rely on measurement of grafted tumours before, during, and after the experimental treatment to ascertain whether the anticancer drug can reduce tumour volume or eliminate it altogether. The measurement of tumour dimensions (length and width) is periodically carried out manually by a technician using vernier callipers. These tumours are typically very complex shapes and the measurement process is open to a large degree of dimensional interpretation and skill. These measurements are then translated in to volume estimates which adds to the method complexity and error. The entire process is cumbersome, time consuming and highly prone to inaccuracies and errors. Due to this known accuracy issue, research organisations compensate for this issue by using more animals in pre-clinical research which is contrary to initiatives to reduce the use of animals in research.Verinnogen has developed a unique 3D surface profiling technology based on the concept of "pin impression" products. The Verinnogen device directly measures and calculates tumour volume with a much higher accuracy than currently possible with callipers. This is in the form of a hand-held, opto-electronic device, that will capture height and shape information of the tumour to a high degree of accuracy in a fraction of the time with an automated process for calculating and recording the volume measurements. By providing a quick, accurate and easy-to-use replacement for callipers, Verinnogen will help expedite translational cancer research, as well as drive reduction in the number of animals used in research.Investment is being sought to enable the team to do research and develop the first functional prototype of this hand-held unit that can be evaluated by real users in research laboratories. This will enable Verinnogen to obtain vital "real" data taken from live animals in existing research studies. This real-world evidence demonstrates accuracy, speed, and utility in pre-clinical trials for anti-cancer therapies which will be vital for future investors and customers alike.

目前，抗癌药物的临床前试验依赖于在实验性治疗之前、期间和之后测量移植肿瘤，以确定抗癌药物是否可以减少肿瘤体积或完全消除肿瘤。肿瘤尺寸（长度和宽度）的测量由技术人员使用游标卡尺定期手动进行。这些肿瘤通常是非常复杂的形状，测量过程在很大程度上取决于尺寸解释和技能。然后将这些测量值转化为体积估计值，这增加了方法的复杂性和误差。整个过程繁琐、耗时，并且非常容易出现不准确和错误。由于这个已知的准确性问题，研究机构通过在临床前研究中使用更多的动物来弥补这个问题，这与减少研究中使用动物的倡议相反。Verinnogen开发了一种独特的3D表面轮廓技术，该技术基于“针印模”产品的概念。Verinnogen设备直接测量和计算肿瘤体积，比目前使用卡尺的准确性高得多。这是一种手持式光电设备，它将在一小部分时间内以高精度捕获肿瘤的高度和形状信息，并自动计算和记录体积测量值。通过提供一种快速、准确和易于使用的卡尺替代品，Verinnogen将有助于加快转化癌症研究，并减少研究中使用的动物数量。目前正在寻求投资，使该团队能够进行研究并开发这种手持式设备的第一个功能原型，可以由研究实验室的真实的用户进行评估。这将使Verinnogen能够在现有的研究中获得从活体动物中获取的重要的“真实的”数据。这一真实世界的证据证明了抗癌疗法临床前试验的准确性、速度和实用性，这对未来的投资者和客户都至关重要。